BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:INOmax (nitric oxide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of INOmax (nitric oxide)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05612074-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:INOmax (nitric oxide): Phase 1 readout est. (NCT05612074)
DESCRIPTION:INOmax (nitric oxide)\, phase 1.\nStudy: Methemoglobin Concentr
 ation in High Dose Inhaled Nitric Oxide\nEstimated primary completion: Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nitric-ox
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05612074
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06159608-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:INOmax (nitric oxide): Phase 1 readout est. (NCT06159608)
DESCRIPTION:INOmax (nitric oxide)\, phase 1.\nStudy: Sex Differences in the
  Vascular Effects of E-cigarette Use\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nitric-oxide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT061
 59608
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06950294-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:INOmax (nitric oxide): Phase 1 readout est. (NCT06950294)
DESCRIPTION:INOmax (nitric oxide)\, phase 1.\nStudy: iNO300 Therapy in Crit
 ically Ill Patients With Pneumonia\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nitric-oxide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06950
 294
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02115724-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT02115724)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: Nitric Oxide Bioavail
 ability and Early Life Stress (NO-Stress)\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nitric-
 oxide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT02115724
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729943-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT07729943)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: A Trial to Study the 
 Effects of Ginseng and Cordyceps on Aerobic Capacity\, Lactate Kinetics\, 
 and Nitric Oxide\nEstimated primary completion: 25 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nitric-oxide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07729943
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04903535-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT04903535)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: External Nitric Oxide
  Measurement Through SNO Degradation\nEstimated primary completion: 30 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nitric-ox
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04903535
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07125443-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT07125443)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: Effect Inhaled Nitric
  Oxide in Adult Liver Transplant\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nitric-oxide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0712
 5443
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832163-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT06832163)
DESCRIPTION:INOmax (nitric oxide)\, phase na\, Persistent Pulmonary Hyperte
 nsion of the Newborn.\nStudy: Close Loop Smart Weaning for INO With PPHN\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nitric-oxide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06832163
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04216927-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:INOmax (nitric oxide): Phase 3 readout est. (NCT04216927)
DESCRIPTION:INOmax (nitric oxide)\, phase 3.\nStudy: NO During CPB in Neona
 tes to Reduce Risk of AKI\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/nitric-oxide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04216927
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334873-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT07334873)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: Effect of Inhaled Nit
 ric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Dist
 ress Syndrome\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nitric-oxide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07334873
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04231760-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:INOmax (nitric oxide): Phase 1/2 readout est. (NCT04231760)
DESCRIPTION:INOmax (nitric oxide)\, phase 1/2.\nStudy: The Effect of Inhale
 d Nitric Oxide on Pulmonary Gas-exchange in COPD\nEstimated primary comple
 tion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nitric-oxide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04231760
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566611-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT07566611)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: Primary Ciliary Dyski
 nesia in Adult Bronchiectasis\nEstimated primary completion: 31 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/nitric-oxide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07566611
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05635851-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:INOmax (nitric oxide): Phase 2 readout est. (NCT05635851)
DESCRIPTION:INOmax (nitric oxide)\, phase 2.\nStudy: NO AD: Use of Nitric O
 xide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During B
 owel Care Following SCI\nEstimated primary completion: February 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nitric-oxide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05635851
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663176-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280205
DTEND;VALUE=DATE:20280206
SUMMARY:INOmax (nitric oxide): Phase 1/2 readout est. (NCT06663176)
DESCRIPTION:INOmax (nitric oxide)\, phase 1/2.\nStudy: Nebulised RESP30X Ni
 tric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)\
 nEstimated primary completion: 5 February 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nitric-oxide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06663176
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05616910-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280328
DTEND;VALUE=DATE:20280329
SUMMARY:INOmax (nitric oxide): Phase 2 readout est. (NCT05616910)
DESCRIPTION:INOmax (nitric oxide)\, phase 2.\nStudy: Inhaled Nitric Oxide f
 or Microvascular Dysfunction in Traumatic Brain Injury\nEstimated primary 
 completion: 28 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nitric-oxide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05616910
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06702553-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:INOmax (nitric oxide): Phase 3 readout est. (NCT06702553)
DESCRIPTION:INOmax (nitric oxide)\, phase 3.\nStudy: Nitric Oxide for Reduc
 ed Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass\nEstim
 ated primary completion: 31 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nitric-oxide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06702553
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485231-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT07485231)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: Nitric Oxide (NO) and
  Endothelial Dysfunction in Women With PTSD\nEstimated primary completion:
  1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nitric-o
 xide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07485231
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04738422-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280715
DTEND;VALUE=DATE:20280716
SUMMARY:INOmax (nitric oxide): Phase 2 readout est. (NCT04738422)
DESCRIPTION:INOmax (nitric oxide)\, phase 2.\nStudy: Determining Airway pH 
 by Compartmental Exhaled Nitric Oxide Levels During Alkaline Buffer Challe
 nge\nEstimated primary completion: 15 July 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nitric-oxide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04738422
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05871606-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:INOmax (nitric oxide): Phase 1 readout est. (NCT05871606)
DESCRIPTION:INOmax (nitric oxide)\, phase 1.\nStudy: Inhaled Nitric Oxide i
 n Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy\nEstim
 ated primary completion: 1 August 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nitric-oxide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05871606
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06675435-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT06675435)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: Inhaled Nitric Oxide 
 in Severe Obesity\nEstimated primary completion: October 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nitric-oxide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06675435
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07544147-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT07544147)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: Inhaled Nitric Oxide 
 for Prevention of Postoperative AKI in High-Risk Cardiac Surgery Patients\
 nEstimated primary completion: 31 October 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nitric-oxide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07544147
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247240-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:INOmax (nitric oxide): Phase 4 readout est. (NCT07247240)
DESCRIPTION:INOmax (nitric oxide)\, phase 4.\nStudy: Efficacy of Inhaled Ni
 tric Oxide in Congenital Diaphragmatic Hernia\nEstimated primary completio
 n: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nit
 ric-oxide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07247240
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05801224-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT05801224)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: Vascular ARDS Recruit
 ment After Inhaled Nitric Oxide\nEstimated primary completion: 31 December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nitric-oxide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05801
 224
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892001-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:INOmax (nitric oxide): Phase na readout est. (NCT07892001)
DESCRIPTION:INOmax (nitric oxide)\, phase na.\nStudy: Modified Inhaled Nitr
 ic Oxide in Ventilated Patients With Acute Respiratory Failure\nEstimated 
 primary completion: 31 December 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nitric-oxide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07892001
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05213676-551@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:INOmax (nitric oxide): Phase 4 readout est. (NCT05213676)
DESCRIPTION:INOmax (nitric oxide)\, phase 4.\nStudy: De-implementing Inhale
 d Nitric Oxide for Congenital Diaphragmatic Hernia\nEstimated primary comp
 letion: 31 October 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nitric-oxide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05213676
URL:https://assetmemo.bio/drug/nitric-oxide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
